PELI1: A Potential Drug Target for Cancer (G57162)

Target Name: PELI1

NCBI ID: G57162

PELI1

PELI1: A Potential Drug Target for Cancer

Pellino homolog 1 (PELI1) is a gene that encodes a protein known to play a critical role in the development and progression of various diseases, including cancer. The protein encoded by PELI1 has been shown to promote the growth and survival of cancer cells, and is Therefore, it is a potential drug target or biomarker for cancer treatment.

PELI1 gene and its function

PELI1 is a member of the Pellino family of proteins, which are characterized by the presence of a specific domain known as the Pellino domain. This domain is known to be involved in the regulation of cellular processes, including cell growth, apoptosis (programmed cell death), and signaling pathways.

PELI1 gene has been shown to be involved in the development and progression of various diseases, including cancer. For example, studies have shown that high levels of PELI1 expression are associated with poor prognosis in patients with pancreatic cancer, a leading cause of cancer-related deaths.

In addition, PELI1 has also been shown to be involved in the development of other diseases, including neurodegenerative disorders, such as Alzheimer's and Parkinson's diseases.

PELI1 as a drug target

PELI1 has been shown to be a potential drug target for cancer treatment. Studies have shown that inhibiting the activity of PELI1 can lead to the inhibition of cancer cell growth and the regression of cancer tumors.

One of the reasons why PELI1 is considered a potential drug target is its role in the regulation of cell signaling pathways. PELI1 has been shown to be involved in the regulation of several signaling pathways, including the PI3K/Akt signaling pathway, which is known to play a role in the regulation of cell growth, survival, and angiogenesis (the formation of new blood vessels).

In addition, PELI1 has also been shown to be involved in the regulation of the NF-kappa-B signaling pathway, which is known to play a role in the regulation of inflammation and cellular responses to stress.

Another reason why PELI1 is considered a potential drug target is its role in the regulation of cell apoptosis. PELI1 has been shown to promote the execution of programmed cell death (apoptosis) in cancer cells, which is thought to be an important step in the regulation of cell growth and the rejection of cancer tumors.

Finally, PELI1 has also been shown to be involved in the regulation of cell adhesion. PELI1 has been shown to be involved in the regulation of cell-cell adhesion, which is thought to play a role in the regulation of cellular behavior and the formation of tissues.

Conclusion

In conclusion, PELI1 is a gene that encodes a protein that has been shown to play a critical role in the development and progression of various diseases, including cancer. The protein encoded by PELI1 has been shown to promote the growth and survival of cancer cells, making it a potential drug target or biomarker for cancer treatment. Further studies are needed to fully understand the role of PELI1 in the regulation of cellular processes and its potential as a drug target.

Protein Name: Pellino E3 Ubiquitin Protein Ligase 1

Functions: E3 ubiquitin ligase catalyzing the covalent attachment of ubiquitin moieties onto substrate proteins. Involved in the TLR and IL-1 signaling pathways via interaction with the complex containing IRAK kinases and TRAF6. Mediates 'Lys-63'-linked polyubiquitination of IRAK1 allowing subsequent NF-kappa-B activation (PubMed:12496252, PubMed:17675297). Mediates 'Lys-48'-linked polyubiquitination of RIPK3 leading to its subsequent proteasome-dependent degradation; preferentially recognizes and mediates the degradation of the 'Thr-182' phosphorylated form of RIPK3 (PubMed:29883609). Negatively regulates necroptosis by reducing RIPK3 expression (PubMed:29883609). Mediates 'Lys-63'-linked ubiquitination of RIPK1 (PubMed:29883609)

The "PELI1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PELI1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets